Eltrombopag

What is Eltrombopag?

Eltrombopag is an orally active, small molecule thrombopoietin receptor agonist. It is a prescription medication primarily used to treat low platelet counts in certain blood disorders. Unlike naturally occurring thrombopoietin, Eltrombopag is not a peptide, allowing it to be administered orally rather than through injection. Its main function is to stimulate the production of platelets, which are crucial for blood clotting and preventing excessive bleeding. It is often prescribed when other treatments have been unsuccessful or are not suitable for the patient.

How Does it Work?

The mechanism of action for Eltrombopag involves its specific binding to and activation of the thrombopoietin receptor (TPO-R) on the surface of hematopoietic stem cells and megakaryocytes in the bone marrow. This binding initiates a signaling cascade that mimics the effects of endogenous thrombopoietin. By activating the TPO-R, Eltrombopag stimulates the proliferation and differentiation of megakaryocytes, which are the precursor cells to platelets. This stimulation ultimately leads to an increased rate of platelet production, thereby raising the platelet count in the bloodstream. It does not directly affect existing platelets but rather enhances the bone marrow's ability to generate new ones. This targeted action helps to restore normal platelet levels, reducing the risk of bleeding events in patients with thrombocytopenia.

Medical Uses

Eltrombopag is approved for the treatment of several serious conditions characterized by low platelet counts:

• Chronic Immune Thrombocytopenia (ITP)

  It is used to treat adults and pediatric patients (1 year and older) with chronic Immune Thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ITP is an autoimmune disorder where the immune system mistakenly attacks and destroys platelets, leading to an increased risk of bruising and bleeding.

• Severe Aplastic Anemia (SAA)

  Eltrombopag is indicated for adult and pediatric patients (2 years and older) with refractory Severe Aplastic Anemia (SAA) who have had an insufficient response to immunosuppressive therapy. SAA is a rare and serious condition where the bone marrow fails to produce enough blood cells, including red blood cells, white blood cells, and platelets.

• Thrombocytopenia in Chronic Hepatitis C

  Historically, Eltrombopag was also used to treat thrombocytopenia in adult patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. However, with the advent of direct-acting antiviral (DAA) therapies, this indication has become less common.

The decision to use Eltrombopag is made by a healthcare professional after careful consideration of the patient's specific condition, medical history, and response to previous treatments.

Dosage

The dosage of Eltrombopag is highly individualized and depends on the specific condition being treated, the patient's age, and their platelet count response. It is crucial to follow the prescribing doctor's instructions precisely.

• Administration: Eltrombopag is taken orally once daily. It should be taken on an empty stomach, at least one hour before or two hours after meals or other medications, especially those containing polyvalent cations (e.g., antacids, dairy products, mineral supplements like iron, calcium, magnesium, aluminum, selenium, and zinc). These substances can bind to Eltrombopag and reduce its absorption, making it less effective.
• Starting Dose:
  • For ITP, the typical starting dose for adults is 50 mg once daily, which may be adjusted based on platelet response. For pediatric ITP patients, the starting dose varies by age.
  • For SAA, the typical starting dose is 50 mg once daily, which can be gradually increased up to 150 mg once daily based on platelet and other blood cell responses.
• Dose Adjustments: Doses are adjusted by the physician based on the patient's platelet count and other clinical factors to achieve and maintain a platelet count sufficient to reduce the risk of bleeding. Regular blood tests are essential to monitor platelet levels and liver function.

Side Effects

Like all medications, Eltrombopag can cause side effects. Some are common and generally mild, while others can be serious.

Common Side Effects:

• Nausea, vomiting, diarrhea, abdominal pain
• Fatigue, headache, dizziness
• Muscle pain, back pain, joint pain
• Upper respiratory tract infection, cough
• Hair loss

Serious Side Effects:

• Liver problems: Eltrombopag can increase liver enzymes. Regular monitoring of liver function tests is required before and during treatment. Symptoms of liver problems include yellowing of the skin or eyes (jaundice), dark urine, unusual tiredness, or pain in the upper right abdomen.
• Blood clots (thromboembolic events): Patients, especially those with chronic liver disease, may have an increased risk of developing blood clots, including deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Bone marrow changes: Eltrombopag stimulates bone marrow, which can lead to new or worsening bone marrow abnormalities. Regular bone marrow examinations may be necessary.
• Cataracts: Some patients, particularly those with SAA, may develop or experience worsening of cataracts.
• Rebound Thrombocytopenia: Stopping Eltrombopag suddenly can lead to a significant drop in platelet count, often below baseline levels, increasing the risk of bleeding.

Patients should report any unusual or severe symptoms to their healthcare provider immediately.

Drug Interactions

Eltrombopag can interact with several other medications and certain foods, which can affect its absorption or metabolism, or alter the effects of other drugs. Key interactions include:

• Polyvalent Cations: As mentioned, substances containing polyvalent cations (e.g., calcium, iron, magnesium, aluminum, selenium, zinc) can chelate Eltrombopag, significantly reducing its absorption. This includes antacids, mineral supplements, and certain foods like dairy products or calcium-fortified juices. Eltrombopag should be taken at least 4 hours before or after these products.
• Statins: Eltrombopag can increase the plasma concentration of statins (e.g., rosuvastatin, atorvastatin) by inhibiting certain drug transporters. If co-administered, a reduced dose of the statin may be required, and patients should be monitored for increased statin-related side effects.
• Protease Inhibitors: Co-administration with certain protease inhibitors, such as lopinavir/ritonavir, may affect Eltrombopag exposure. Dose adjustments may be necessary.
• Other Medications: Eltrombopag is a substrate for certain drug-metabolizing enzymes and transporters. Concomitant use with inhibitors or inducers of these pathways may alter Eltrombopag levels. Always inform your doctor about all medications, supplements, and herbal products you are taking.

FAQ

• Is Eltrombopag a chemotherapy drug?

  No, Eltrombopag is not a chemotherapy drug. It is a thrombopoietin receptor agonist that specifically stimulates platelet production, rather than directly killing cancer cells or suppressing the immune system in the same way traditional chemotherapy does.

• How long does it take for Eltrombopag to increase platelet counts?

  Patients typically begin to see an increase in platelet counts within 1 to 2 weeks of starting Eltrombopag treatment. However, the full effect and stabilization of platelet counts may take longer, especially for conditions like severe aplastic anemia.

• Can I stop taking Eltrombopag if my platelet count is normal?

  You should never stop taking Eltrombopag without consulting your doctor. Discontinuing the medication suddenly can lead to a significant drop in platelet counts, often below baseline levels, and increase the risk of bleeding. Your doctor will provide a plan for dose reduction or discontinuation if appropriate.

• Is Eltrombopag safe during pregnancy or breastfeeding?

  Eltrombopag is generally not recommended during pregnancy due to potential risks to the fetus. It is unknown if Eltrombopag is excreted in human milk, but due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment. Always discuss pregnancy and breastfeeding plans with your healthcare provider.

Products containing Eltrombopag are available through trusted online pharmacies. You can browse Eltrombopag-based medications at ShipperVIP or Medicenter.

Summary

Eltrombopag is a vital oral medication that acts as a thrombopoietin receptor agonist, effectively stimulating the bone marrow to produce more platelets. It plays a crucial role in managing chronic Immune Thrombocytopenia (ITP) and refractory Severe Aplastic Anemia (SAA), offering a lifeline to patients with dangerously low platelet counts. While highly effective, its use requires careful adherence to dosage instructions, diligent monitoring for potential side effects, and awareness of significant drug and food interactions. Patients undergoing Eltrombopag treatment should maintain close communication with their healthcare team to ensure optimal outcomes and minimize risks, ultimately enhancing their quality of life by reducing the incidence of bleeding events.